At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
Panobinostat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Panobinostat and Ruxolitinib In MyElofibrosis (PRIME STUDY) - Phase I/II Study of Combination Oral JAK2 Tyrosine Kinase Inhibitor (JAK2-TKI) and Histone Deacetylase Inhibitor (HDACI) Therapy in Patients With Myelofibrosis
In Brief
A Phase 2 clinical trial evaluating Panobinostat and Ruxolitinib for Myelofibrosis. Completed, enrolled 15 participants across 1 site.
Detailed Summary
This is a single-center, single arm, dose finding study to assess safety and tolerability of the oral combination of Panobinostat and Ruxolitinib in patients with myelofibrosis (MF) in chronic and accelerated phase.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyelofibrosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 2012
Enrollment StartJan 2013
Primary CompletionMay 2018
TodayJul 2026
First PostedSep 26, 2012
Enrollment StartJan 1, 2013
Primary CompletionMay 18, 2018
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 13.8 years ago
Interventions
Panobinostatdrug
PO TIW QOW or PO TIW QW
Ruxolitinibdrug
PO BID x 28 days